Literature DB >> 12557436

[Value of interleukin-8 determination in diagnosis of benign and malignant breast tumor].

Irena Zakrzewska1, Leszek Kozłowski, Marek Wojtukiewicz.   

Abstract

The studies were performed in women with breast carcinoma, benign breast tumour and in a control group. Serum levels of IL-8 were determined 1-2 days before surgical procedure, according to the enzyme-linked immunosorbent assay (ELISA). Pretreatment levels of IL-8 were significantly increased in carcinoma patients in relation to the benign tumour and the control group. The frequency of increased results and absolute values of IL-8 levels showed tendency to significant increase with the stage of disease. These results suggested that IL-8 measurement may be useful in estimation of disease progression in women with breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12557436

Source DB:  PubMed          Journal:  Pol Merkur Lekarski        ISSN: 1426-9686


  3 in total

1.  IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Authors:  Romaine I Fernando; Marianne D Castillo; Mary Litzinger; Duane H Hamilton; Claudia Palena
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

2.  Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans.

Authors:  Archana Kamalakar; Manali S Bendre; Charity L Washam; Tristan W Fowler; Adam Carver; Joshua D Dilley; John W Bracey; Nisreen S Akel; Aaron G Margulies; Robert A Skinner; Frances L Swain; William R Hogue; Corey O Montgomery; Parshawn Lahiji; Jacqueline J Maher; Kim E Leitzel; Suhail M Ali; Alan Lipton; Richard W Nicholas; Dana Gaddy; Larry J Suva
Journal:  Bone       Date:  2014-01-28       Impact factor: 4.398

3.  Loss of COX5B inhibits proliferation and promotes senescence via mitochondrial dysfunction in breast cancer.

Authors:  Shui-Ping Gao; He-Fen Sun; Hong-Lin Jiang; Liang-Dong Li; Xin Hu; Xiao-En Xu; Wei Jin
Journal:  Oncotarget       Date:  2015-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.